V Gounant1, S Brosseau1,2, G Soussi1
1Université de Paris, Service d'Oncologie thoracique-CIC INSERM 1425, Institut Universitaire du Cancer Paris-Nord, Hôpital Bichat-Claude Bernard, Assistance Publique-Hôpitaux de Paris (AP-HP) 46 rue Henri Huchard, 75018 Paris, Paris, France.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Cancer patients face higher COVID-19 risks and mortality. Lung and hematological cancers pose the greatest threats, while immune checkpoint inhibitors may not worsen outcomes. Vaccination requires careful timing, especially post-chemotherapy.
Area of Science: